Current Edition

blood

Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial

Oral semaglutide, an investigational GLP-1 analogue taken as a once-daily tablet, achieved significant reductions in blood sugar versus placebo in adults with type 2 diabetes, …

Continue Reading →
Europe

Novo’s oral semaglutide outperforms Jardiance in late-stage study

Danish drugmaker Novo Nordisk said Tuesday its PIONEER 2 study testing oral semaglutide in patients with type 2 diabetes met its primary objective, showing a …

Continue Reading →
data

Semaglutide Injection Phase 2 Data Presented at ENDO Demonstrated Significant Weight Loss in Adults With Obesity

Adults with obesity treated with semaglutide 0.4 mg administered once-daily via subcutaneous injections lost up to 13.8% of their body weight after 52 weeks in …

Continue Reading →